12 recruiting, 8 completed, 5 active not recruiting, 4 terminated. 33 Phase 1, 11 Phase 2.
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Patients With Metastatic Castration-Resistant Prostate Cancer FX-111 - Metastatic Castration Resistant Prostate Cancer, mCRPC | Phase 1 | Recruiting | Flare Therapeutics Inc. | 60 | 2026-07-01 | 2026-09-24 |
| A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer TD001 - Metastatic Castration-Resistant Prostatic Cancer | Phase 1 / Phase 2 | Recruiting | T.O.A.D. Oncology SA | 180 | 2026-01-30 | 2026-05-29 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-09-25 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 394 | 2024-03-06 | 2026-10-28 |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1 / Phase 2 | Recruiting | Celcuity Inc | 54 | 2024-01-01 | 2026-04-13 |
| Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer TVB-2640, Enzalutamide - Prostatic Neoplasms, Castration-Resistant | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 8 | 2023-11-20 | 2026-10-26 |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986460 - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Bristol-Myers Squibb | 140 | 2023-10-18 | 2026-08-10 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel - Hormone-refractory Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 347 | 2023-08-10 | 2026-10-27 |
| HTL0039732 in Participants With Advanced Solid Tumours HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 150 | 2023-08-02 | 2026-10-01 |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) JANX007, Darolutamide - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 272 | 2022-09-15 | 2026-10-29 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy Radionuclide Therapy - Prostatic Neoplasms, Castration-Resistant | Phase 1 | Unknown | Erasmus Medical Center | 30 | 2021-12-29 | 2023-06-13 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Clarity Pharmaceuticals Ltd | 54 | 2021-08-11 | 2026-05-06 |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer 225^Ac-PSMA-617, 68^Ga-PSMA-11 - Prostatic Neoplasms, Castration-Resistant | Phase 1 | Active not recruiting | Endocyte | 101 | 2021-04-01 | 2026-04-30 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
Showing 20 of 33. Sign in to see all of them.
Prostatic Neoplasms (14) · Neoplasms (8) · Neoplasms by Site (4) · Pancreatic Neoplasms (4) · Prostatic Diseases (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Melanoma (3) · Ovarian Neoplasms (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Urogenital Neoplasms (3)
Genital Diseases (32) · Urogenital Diseases (32) · Male Urogenital Diseases (31) · Genital Diseases, Male (30) · Genital Neoplasms, Male (30) · Urogenital Neoplasms (30) · Neoplasms by Site (29) · Prostatic Diseases (29) · Neoplasms (25) · Prostatic Neoplasms (19) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms, Glandular and Epithelial (7) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6)
enzalutamide (8) · Docetaxel (5) · darolutamide (2) · olaparib (2) · (225)Ac-PSMA-617 (1) · Dexamethasone (1) · JNJ-64264681 (1) · JNJ-64619178 (1) · Pioglitazone (1) · Prednisone (1) · Rosuvastatin Calcium (1) · TVB-2640 (1) · abiraterone (1) · apalutamide (1) · atezolizumab (1)
Janssen Research & Development, LLC (3) · Nuvation Bio Inc. (3) · Cancer Research UK (2) · MacroGenics (2) · Merck Sharp & Dohme LLC (2) · Aragon Pharmaceuticals, Inc. (1) · Arcus Biosciences, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Celcuity Inc (1) · Celgene (1) · Clarity Pharmaceuticals Ltd (1) · Endocyte (1) · Erasmus Medical Center (1)
United States (22) · Spain (12) · United Kingdom (10) · Australia (9) · France (9) · Canada (6) · South Korea (6) · Italy (5) · Netherlands (4) · Poland (4) · Taiwan (4) · Germany (3) · Israel (3) · Japan (3) · Belgium (2)
David Nanus, M.D. (1) · Denise Casey, M.D. (1) · Helmut R Salih, Prof. (1) · J C W, M.D,Ph.D (1)
PMID 31446511, PMID 32878613, PMID 33067297, PMID 35110356, PMID 38287346, PMID 39293515, PMID 42558019
2023 (3), 2019 (2), 2015 (1), 2018 (1), 2025 (1)